Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial

The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system. In a multi-center randomized co...

Full description

Saved in:
Bibliographic Details
Published inJournal of Korean medical science Vol. 34; no. 14; pp. e110 - 13
Main Authors Jeon, Kyeongman, Suh, Jae Kyung, Jang, Eun Jin, Cho, Songhee, Ryu, Ho Geol, Hong, Sang-Bum, Lee, Hyun Joo, Kim, Jae Yeol, Lee, Sang-Min
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Academy of Medical Sciences 15.04.2019
대한의학회
Subjects
Online AccessGet full text
ISSN1011-8934
1598-6357
1598-6357
DOI10.3346/jkms.2019.34.e110

Cover

Abstract The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system. In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation. The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days; = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis. PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes. ClinicalTrials.gov Identifier: NCT02202941.
AbstractList The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system.BACKGROUNDThe objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system.In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation.METHODSIn a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation.The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; P = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days; P = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis.RESULTSThe two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; P = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days; P = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis.PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes.CONCLUSIONPCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes.ClinicalTrials.gov Identifier: NCT02202941.TRIAL REGISTRATIONClinicalTrials.gov Identifier: NCT02202941.
Background: The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system. Methods: In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost- minimization analysis of PCT-guided antibiotic discontinuation. Results: The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; P = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6–10 days vs. 14 days; IQR, 12–21 days; P = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT- guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis.Conclusion: PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes. KCI Citation Count: 2
The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with sepsis in a country with a high prevalence of antimicrobial resistance and a national health insurance system. In a multi-center randomized controlled trial, patients were randomly assigned to a PCT group (stopping antibiotics based on a predefined cut-off range of PCT) or a control group. The primary end-point was antibiotic duration. We also performed a cost-minimization analysis of PCT-guided antibiotic discontinuation. The two groups (23 in the PCT group and 29 in the control group) had similar demographic and clinical characteristics except for need for renal replacement therapy on ICU admission (46% vs. 14%; = 0.010). In the per-protocol analysis, the median duration of antibiotic treatment for sepsis was 4 days shorter in the PCT group than the control group (8 days; interquartile range [IQR], 6-10 days vs. 14 days; IQR, 12-21 days; = 0.001). However, main secondary outcomes, such as clinical cure, 28-day mortality, hospital mortality, and ICU and hospital stays were not different between the two groups. In cost evaluation, PCT-guided therapy decreased antibiotic costs by USD 30 (USD 241 in the PCT group vs. USD 270 in the control group). The results of the intention-to-treat analysis were similar to those obtained for the per-protocol analysis. PCT-guided antibiotic discontinuation in critically ill patients with sepsis could reduce the duration of antibiotic use and its costs with no apparent adverse outcomes. ClinicalTrials.gov Identifier: NCT02202941.
Author Cho, Songhee
Suh, Jae Kyung
Hong, Sang-Bum
Lee, Sang-Min
Jang, Eun Jin
Kim, Jae Yeol
Ryu, Ho Geol
Lee, Hyun Joo
Jeon, Kyeongman
AuthorAffiliation 2 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea
7 Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
10 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
5 Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
9 Department of Internal Medicine, Chung Ang University College of Medicine, Seoul, Korea
1 Department of Critical Care Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea
3 National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea
8 Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospit
AuthorAffiliation_xml – name: 6 Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea
– name: 7 Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
– name: 1 Department of Critical Care Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea
– name: 5 Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
– name: 4 Department of Information Statistics, Andong National University, Andong, Korea
– name: 8 Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
– name: 2 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea
– name: 9 Department of Internal Medicine, Chung Ang University College of Medicine, Seoul, Korea
– name: 3 National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea
– name: 10 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Kyeongman
  orcidid: 0000-0002-4822-1772
  surname: Jeon
  fullname: Jeon, Kyeongman
  organization: Department of Critical Care Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea
– sequence: 2
  givenname: Jae Kyung
  orcidid: 0000-0002-9804-2983
  surname: Suh
  fullname: Suh, Jae Kyung
  organization: National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea
– sequence: 3
  givenname: Eun Jin
  orcidid: 0000-0002-9137-9815
  surname: Jang
  fullname: Jang, Eun Jin
  organization: National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea., Department of Information Statistics, Andong National University, Andong, Korea
– sequence: 4
  givenname: Songhee
  orcidid: 0000-0003-2192-7182
  surname: Cho
  fullname: Cho, Songhee
  organization: National Evidence-based Healthcare Collaborating Agency, Ministry of Health and Welfare, Korea
– sequence: 5
  givenname: Ho Geol
  orcidid: 0000-0001-8952-6049
  surname: Ryu
  fullname: Ryu, Ho Geol
  organization: Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
– sequence: 7
  givenname: Sang-Bum
  orcidid: 0000-0002-4424-7457
  surname: Hong
  fullname: Hong, Sang-Bum
  organization: Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
– sequence: 8
  givenname: Hyun Joo
  orcidid: 0000-0002-1223-4387
  surname: Lee
  fullname: Lee, Hyun Joo
  organization: Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
– sequence: 9
  givenname: Jae Yeol
  orcidid: 0000-0003-3631-4610
  surname: Kim
  fullname: Kim, Jae Yeol
  organization: Department of Internal Medicine, Chung Ang University College of Medicine, Seoul, Korea
– sequence: 10
  givenname: Sang-Min
  orcidid: 0000-0002-1388-9318
  surname: Lee
  fullname: Lee, Sang-Min
  organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30977312$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002457335$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9Uk1v1DAUtFAR_YAfwAX52B6y2LHjJByQVlsolYq6Wpaz5XVeqFvH3toOUvkV_GSc3VIBB07vyW9mnu2ZY3TgvAOEXlMyY4yLt7d3Q5yVhLYzxmdAKXmGjmjVNoVgVX2Qe0Jp0bSMH6LjGG8JKauqZC_QISNtXTNaHqGfy-C1stok74wrLkbTQYfXAVQawCXsHT4fg0omN77Hc5fMxvhkNF7fQFDbB6xchxc-Jmwc_gLbabTM-EyO-HS5uj6fn73DCn8ebTLFIh9DwKtM8oP5ARPVpeCt3W01yr5Ez3tlI7x6rCfo68cP68Wn4ur64nIxvyo0ZywVjFagNa1K3rG64SA2HWt7IgRRQhNSA2lFpTjnhDUVpzXTuhEbIXoNXFDQ7ASd7XVd6OWdNtIrs6vfvLwLcr5aX0re5L-tRMa-32O342aATudHBGXlNphBhYcd8--JMzdZ57sUXBBKJoHTR4Hg70eISQ4marBWOfBjlGVJ2uwba8oMffPnrqclvy3LALoH6OBjDNA_QSiRUyzkFAs5xUIyLqdYZE79DycbvjM1X9fY_zB_AWJAvs8
CitedBy_id crossref_primary_10_4103_picr_picr_298_23
crossref_primary_10_1016_j_jointm_2022_10_001
crossref_primary_10_1002_phar_2834
crossref_primary_10_1080_14787210_2021_1932462
crossref_primary_10_3346_jkms_2019_34_e122
crossref_primary_10_1016_j_cca_2021_01_004
crossref_primary_10_1080_23744235_2022_2037701
crossref_primary_10_3947_ic_2022_0170
crossref_primary_10_1080_14737159_2023_2242782
crossref_primary_10_1080_10408363_2021_1975637
crossref_primary_10_1177_11772719241298197
crossref_primary_10_36106_ijsr_5217256
crossref_primary_10_1097_CCM_0000000000006366
crossref_primary_10_5124_jkma_2019_62_12_638
crossref_primary_10_23736_S0031_0808_19_03809_6
crossref_primary_10_1080_14737159_2020_1782193
crossref_primary_10_3389_fmed_2023_1080007
crossref_primary_10_1097_QCO_0000000000000707
crossref_primary_10_1186_s40560_025_00776_0
crossref_primary_10_5005_jp_journals_10071_24326
crossref_primary_10_1007_s40274_019_5868_8
crossref_primary_10_1002_ams2_70037
crossref_primary_10_3390_antibiotics11030367
crossref_primary_10_1097_CCE_0000000000000571
Cites_doi 10.1586/eri.10.25
10.1186/1471-2334-13-158
10.1007/s00423-008-0432-1
10.3111/13696998.2015.1064934
10.1164/rccm.200708-1238OC
10.1097/CCM.0b013e31821201a5
10.1093/jac/dku497
10.1007/s001340050644
10.1016/S0140-6736(15)00474-2
10.1164/rccm.201408-1483OC
10.1001/archinternmed.2012.770
10.1136/bmjopen-2012-002186
10.1097/MD.0000000000002100
10.1097/CCM.0b013e31821e8791
10.1097/CCM.0b013e31827e83af
10.1016/S0140-6736(09)61879-1
10.1186/cc7903
10.1016/S1473-3099(16)00053-0
10.1016/S1473-3099(14)70780-7
10.1164/rccm.200512-1922OC
10.1016/j.diagmicrobio.2013.03.027
10.1097/CCM.0000000000001294
10.3947/ic.2014.46.2.84
10.1097/CCM.0000000000002255
10.1086/315214
10.1001/archinternmed.2011.318
10.1002/jhm.988
10.1093/cid/cix179
10.1017/ice.2014.60
ContentType Journal Article
Copyright 2019 The Korean Academy of Medical Sciences.
2019 The Korean Academy of Medical Sciences. 2019 The Korean Academy of Medical Sciences
Copyright_xml – notice: 2019 The Korean Academy of Medical Sciences.
– notice: 2019 The Korean Academy of Medical Sciences. 2019 The Korean Academy of Medical Sciences
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3346/jkms.2019.34.e110
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1598-6357
EndPage 13
ExternalDocumentID oai_kci_go_kr_ARTI_4801956
PMC6460106
30977312
10_3346_jkms_2019_34_e110
Genre Randomized Controlled Trial
Multicenter Study
Journal Article
GrantInformation_xml – fundername: Ministry of Health and Welfare
  grantid: NA14-003
– fundername: ;
  grantid: NA14-003
GroupedDBID ---
29K
2WC
3O-
5-W
53G
5GY
8JR
8XY
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EF.
EJD
F5P
FRP
GROUPED_DOAJ
GX1
HYE
KQ8
M48
O5R
O5S
OK1
OVT
PGMZT
RNS
RPM
TR2
W2D
XSB
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c433t-315ecc1524d3784e6bd39f0660a6c007e0965a44403854173cc86b66fce461ec3
IEDL.DBID M48
ISSN 1011-8934
1598-6357
IngestDate Sun Mar 09 07:53:44 EDT 2025
Thu Aug 21 13:18:30 EDT 2025
Thu Jul 10 18:10:26 EDT 2025
Thu Apr 03 07:00:54 EDT 2025
Tue Jul 01 01:45:01 EDT 2025
Thu Apr 24 23:07:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 14
Keywords Economics
Biomarkers
Sepsis
Anti-Bacterial Agents
Intensive Care Unit
Calcitonin
Language English
License 2019 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c433t-315ecc1524d3784e6bd39f0660a6c007e0965a44403854173cc86b66fce461ec3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Kyeongman Jeon and Jae Kyung Suh contributed equally to this work.
ORCID 0000-0002-1388-9318
0000-0002-4822-1772
0000-0002-1223-4387
0000-0002-9804-2983
0000-0001-8952-6049
0000-0003-3631-4610
0000-0002-4424-7457
0000-0002-9137-9815
0000-0003-2192-7182
0000-0002-1170-8042
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2019.34.e110
PMID 30977312
PQID 2209598382
PQPubID 23479
PageCount 13
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_4801956
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6460106
proquest_miscellaneous_2209598382
pubmed_primary_30977312
crossref_primary_10_3346_jkms_2019_34_e110
crossref_citationtrail_10_3346_jkms_2019_34_e110
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-04-15
PublicationDateYYYYMMDD 2019-04-15
PublicationDate_xml – month: 04
  year: 2019
  text: 2019-04-15
  day: 15
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of Korean medical science
PublicationTitleAlternate J Korean Med Sci
PublicationYear 2019
Publisher The Korean Academy of Medical Sciences
대한의학회
Publisher_xml – name: The Korean Academy of Medical Sciences
– name: 대한의학회
References de Jong (10.3346/jkms.2019.34.e110_ref13) 2016; 16
Hochreiter (10.3346/jkms.2019.34.e110_ref7) 2009; 13
Jensen (10.3346/jkms.2019.34.e110_ref14) 2011; 39
Kip (10.3346/jkms.2019.34.e110_ref30) 2015; 18
File (10.3346/jkms.2019.34.e110_ref3) 2012; 7
Van Boeckel (10.3346/jkms.2019.34.e110_ref16) 2014; 14
Svoboda (10.3346/jkms.2019.34.e110_ref5) 2007; 54
Christ-Crain (10.3346/jkms.2019.34.e110_ref19) 2006; 174
Schuetz (10.3346/jkms.2019.34.e110_ref23) 2011; 171
Howard (10.3346/jkms.2019.34.e110_ref25) 2015; 70
Deliberato (10.3346/jkms.2019.34.e110_ref11) 2013; 76
Gogos (10.3346/jkms.2019.34.e110_ref21) 2000; 181
World Health Organization (10.3346/jkms.2019.34.e110_ref17) 2014
Chu (10.3346/jkms.2019.34.e110_ref26) 2017; 64
Laxminarayan (10.3346/jkms.2019.34.e110_ref4) 2016; 387
Heyland (10.3346/jkms.2019.34.e110_ref28) 2011; 39
Meisner (10.3346/jkms.2019.34.e110_ref32) 1998; 24
Harrison (10.3346/jkms.2019.34.e110_ref29) 2015; 36
Dellinger (10.3346/jkms.2019.34.e110_ref1) 2013; 41
Albrich (10.3346/jkms.2019.34.e110_ref27) 2012; 172
Rhodes (10.3346/jkms.2019.34.e110_ref24) 2017; 45
Annane (10.3346/jkms.2019.34.e110_ref10) 2013; 3
Yong (10.3346/jkms.2019.34.e110_ref18) 2014; 46
Schroeder (10.3346/jkms.2019.34.e110_ref8) 2009; 394
Thomas (10.3346/jkms.2019.34.e110_ref2) 2015; 43
10.3346/jkms.2019.34.e110_ref31
Shehabi (10.3346/jkms.2019.34.e110_ref12) 2014; 190
Yoon (10.3346/jkms.2019.34.e110_ref20) 2015; 94
Bouadma (10.3346/jkms.2019.34.e110_ref9) 2010; 375
Hohn (10.3346/jkms.2019.34.e110_ref15) 2013; 13
Nobre (10.3346/jkms.2019.34.e110_ref6) 2008; 177
Schuetz (10.3346/jkms.2019.34.e110_ref22) 2010; 8
30977318 - J Korean Med Sci. 2019 Apr 15;34(14):e122
References_xml – volume: 8
  start-page: 575
  issue: 5
  year: 2010
  ident: 10.3346/jkms.2019.34.e110_ref22
  publication-title: Expert Rev Anti Infect Ther
  doi: 10.1586/eri.10.25
– volume: 13
  start-page: 158
  issue: 1
  year: 2013
  ident: 10.3346/jkms.2019.34.e110_ref15
  publication-title: BMC Infect Dis
  doi: 10.1186/1471-2334-13-158
– volume-title: Antimicrobial Resistance: Global Report on Surveillance
  year: 2014
  ident: 10.3346/jkms.2019.34.e110_ref17
– volume: 394
  start-page: 221
  issue: 2
  year: 2009
  ident: 10.3346/jkms.2019.34.e110_ref8
  publication-title: Langenbecks Arch Surg
  doi: 10.1007/s00423-008-0432-1
– volume: 18
  start-page: 944
  issue: 11
  year: 2015
  ident: 10.3346/jkms.2019.34.e110_ref30
  publication-title: J Med Econ
  doi: 10.3111/13696998.2015.1064934
– volume: 177
  start-page: 498
  issue: 5
  year: 2008
  ident: 10.3346/jkms.2019.34.e110_ref6
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200708-1238OC
– volume: 39
  start-page: 1792
  issue: 7
  year: 2011
  ident: 10.3346/jkms.2019.34.e110_ref28
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e31821201a5
– volume: 70
  start-page: 1245
  issue: 4
  year: 2015
  ident: 10.3346/jkms.2019.34.e110_ref25
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dku497
– volume: 24
  start-page: 680
  issue: 7
  year: 1998
  ident: 10.3346/jkms.2019.34.e110_ref32
  publication-title: Intensive Care Med
  doi: 10.1007/s001340050644
– volume: 387
  start-page: 168
  issue: 10014
  year: 2016
  ident: 10.3346/jkms.2019.34.e110_ref4
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)00474-2
– volume: 190
  start-page: 1102
  issue: 10
  year: 2014
  ident: 10.3346/jkms.2019.34.e110_ref12
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201408-1483OC
– volume: 172
  start-page: 715
  issue: 9
  year: 2012
  ident: 10.3346/jkms.2019.34.e110_ref27
  publication-title: Arch Intern Med
  doi: 10.1001/archinternmed.2012.770
– volume: 3
  start-page: e002186
  issue: 2
  year: 2013
  ident: 10.3346/jkms.2019.34.e110_ref10
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2012-002186
– volume: 94
  start-page: e2100
  issue: 46
  year: 2015
  ident: 10.3346/jkms.2019.34.e110_ref20
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000002100
– volume: 39
  start-page: 2048
  issue: 9
  year: 2011
  ident: 10.3346/jkms.2019.34.e110_ref14
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e31821e8791
– volume: 41
  start-page: 580
  issue: 2
  year: 2013
  ident: 10.3346/jkms.2019.34.e110_ref1
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e31827e83af
– volume: 375
  start-page: 463
  issue: 9713
  year: 2010
  ident: 10.3346/jkms.2019.34.e110_ref9
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)61879-1
– volume: 54
  start-page: 359
  issue: 74
  year: 2007
  ident: 10.3346/jkms.2019.34.e110_ref5
  publication-title: Hepatogastroenterology
– volume: 13
  start-page: R83
  issue: 3
  year: 2009
  ident: 10.3346/jkms.2019.34.e110_ref7
  publication-title: Crit Care
  doi: 10.1186/cc7903
– volume: 16
  start-page: 819
  issue: 7
  year: 2016
  ident: 10.3346/jkms.2019.34.e110_ref13
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(16)00053-0
– volume: 14
  start-page: 742
  issue: 8
  year: 2014
  ident: 10.3346/jkms.2019.34.e110_ref16
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(14)70780-7
– volume: 174
  start-page: 84
  issue: 1
  year: 2006
  ident: 10.3346/jkms.2019.34.e110_ref19
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200512-1922OC
– volume: 76
  start-page: 266
  issue: 3
  year: 2013
  ident: 10.3346/jkms.2019.34.e110_ref11
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2013.03.027
– volume: 43
  start-page: 2527
  issue: 12
  year: 2015
  ident: 10.3346/jkms.2019.34.e110_ref2
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000001294
– volume: 46
  start-page: 84
  issue: 2
  year: 2014
  ident: 10.3346/jkms.2019.34.e110_ref18
  publication-title: Infect Chemother
  doi: 10.3947/ic.2014.46.2.84
– volume: 45
  start-page: 486
  issue: 3
  year: 2017
  ident: 10.3346/jkms.2019.34.e110_ref24
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000002255
– volume: 181
  start-page: 176
  issue: 1
  year: 2000
  ident: 10.3346/jkms.2019.34.e110_ref21
  publication-title: J Infect Dis
  doi: 10.1086/315214
– volume: 171
  start-page: 1322
  issue: 15
  year: 2011
  ident: 10.3346/jkms.2019.34.e110_ref23
  publication-title: Arch Intern Med
  doi: 10.1001/archinternmed.2011.318
– volume: 7
  start-page: S22
  issue: Suppl 1
  year: 2012
  ident: 10.3346/jkms.2019.34.e110_ref3
  publication-title: J Hosp Med
  doi: 10.1002/jhm.988
– ident: 10.3346/jkms.2019.34.e110_ref31
– volume: 64
  start-page: 1509
  issue: 11
  year: 2017
  ident: 10.3346/jkms.2019.34.e110_ref26
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cix179
– volume: 36
  start-page: 265
  issue: 3
  year: 2015
  ident: 10.3346/jkms.2019.34.e110_ref29
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1017/ice.2014.60
– reference: 30977318 - J Korean Med Sci. 2019 Apr 15;34(14):e122
SSID ssj0025523
Score 2.319008
Snippet The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill patients with...
Background: The objective of this study was to establish the efficacy and safety of procalcitonin (PCT)-guided antibiotic discontinuation in critically ill...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e110
SubjectTerms Aged
Anti-Bacterial Agents - economics
Anti-Bacterial Agents - therapeutic use
Biomarkers - analysis
Cost of Illness
Critical Illness
Female
Hospital Mortality
Humans
Intensive Care Units
Kaplan-Meier Estimate
Male
Middle Aged
Original
Procalcitonin - analysis
Sepsis - drug therapy
Sepsis - mortality
Sepsis - pathology
Single-Blind Method
의학일반
Title Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial
URI https://www.ncbi.nlm.nih.gov/pubmed/30977312
https://www.proquest.com/docview/2209598382
https://pubmed.ncbi.nlm.nih.gov/PMC6460106
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002457335
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Korean Medical Science, 2019, 34(14), , pp.1-13
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ti9NAEF7OE8Qv4vlaX8oqflAhpdudbFJBpNx53inV42zhvi3bza6G9jaatuDdr7if7EySFitF8FMI2ReS2ck8szPzLGMvpKnKKVHTvDER4ttulJrYRwIcmL7B_2HlKA4_q6MxfDyLz3bY6nir5gPOt7p2dJ7UuJx1fv28eIcK_5Y8TkkRyuk5EW-LfkdCxwkquLqOhkmRLzaEdVABwXOvzrcXIkIzDXWQc_sQG2bqWij9NgT6dyLlH5bp8Da71UBKPqjXwB7bceEOuzFsguZ32RUVA5iZRd0NeYg-LPPMZXy0yjDnReAHy3oh8MLzQaAykgIH46OacoCbkPH9Yr7geeBfKQ3G8pOaj3XOX56cfjkYvHrDDa-KeSPaL3YlP8VOxXl-6ahrlQ4_q2bF9X6PjQ_fj_aPouYghsiClAv8T8coabT0kMkkBacmmex7BCtdoyyCDEcUMgYAKMwIIpHWpmqilLcOlHBW3me7oQjuIePeeQOZAdH3BA582pPSJskEkZ-NjVEt1l19d20blnI6LGOm0VshUWkSlSZRaQmaRNVir9ddftQUHf9q_ByFqac210SsTddvhZ6WGt2HY01cOugwttizlaw1ahuFUExwxRKH6tG-aSrTXos9qGW_nlN2EUtLgU-SjVWxbkATbj4J-feK0VtBFe5-9D9v8pjdpFuKbIn4CdtdlEv3FAHSYtJG1-D4U7vaXmhXKvAbrisPpQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Procalcitonin-Guided+Treatment+on+Duration+of+Antibiotic+Therapy+and+Cost+in+Septic+Patients+%28PRODA%29%3A+a+Multi-Center+Randomized+Controlled+Trial&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Jeon%2C+Kyeongman&rft.au=Suh%2C+Jae+Kyung&rft.au=Jang%2C+Eun+Jin&rft.au=Cho%2C+Songhee&rft.date=2019-04-15&rft.issn=1011-8934&rft.eissn=1598-6357&rft.volume=34&rft.issue=14&rft_id=info:doi/10.3346%2Fjkms.2019.34.e110&rft.externalDBID=n%2Fa&rft.externalDocID=10_3346_jkms_2019_34_e110
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon